We investigated the influence of
T-593, a novel anti-
ulcer agent, on the recurrence and relapse of cryocautery-induced
gastric ulcer in rats, in comparison with the action of
famotidine and
ranitidine. The drugs were administered from the 7th to the 119th day and then discontinued to the 190th day after induction of
gastric ulcer. The healing, recurrence and relapse process of
gastric ulcer was sequentially observed with an
endoscope. In the control group, the reduction of
ulcer index was observed until the 76th day after
ulcer induction followed by aggravation, suggesting the recurrence and relapse occurred on cryocautery-induced
gastric ulcer in rats. In the
famotidine and
ranitidine groups, the recurrence and relapse occurred after cessation of administration. The recurrence and/or relapse rate of
T-593 was lower than those of other drugs. In the histological measurement, the grades of heterotopic regenerated gland and inflammatory cell infiltration of
T-593 was lower than those of the control and other drugs in the
ulcer area. From these results, it is concluded that
T-593 induces
ulcer healing with a lower recurrence and/or relapse rate of
ulcers than other conventional H2-antagonists, and
T-593 may thus be a useful anti-
ulcer drug for clinical
therapy.